Lizhu Group: Type 1 innovative drug Lekon Qita monoclonal antibody psoriasis indications have been included in the CDE priority review and are expected to be approved within the year.

On May 21st, at the performance briefing, Lize Group stated that regarding the landing of innovative pharmaceutical business: On one hand, from the perspective of already marketed varieties, this year is the first year after the inclusion of the adenomyosis indication of Alipazole microspheres and Qu Purilin microspheres in medical insurance. The company is actively promoting progress in hospital admission, and the current progress is consistent with the plan; on the other hand, from the perspective of varieties about to be approved, Category 1 innovative drug Lekanjita monoclonal antibody for Psoriasis indications was included in the CDE priority review in January this year and is expected to be approved within the year; in addition, the company is actively promoting the market entry process of P-CAB product JP-1366 tablets in the digestive field and recombinant human follicle-stimulating hormone in the field of assisted reproduction.